NC
XENE icon

Nexthera Capital’s Xenon Pharmaceuticals XENE Stock Holding History

Nexthera Capital’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-379,071
Closed -$1.86M – 55
2018
Q1 		$1.86M Buy
+379,071
New +$1.4M 0.31% 39

Other funds holding XENE

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Nexthera Capital's XENE Position: Q2 2018 in Review

Nexthera Capital sold out of Xenon Pharmaceuticals (XENE) in Q2 2018, closing a stake of 379,071 shares — an estimated $1.86M sold.

Nexthera Capital first reported a position in XENE in Q1 2018 and held it in 1 quarter. The position peaked at $1.86M in Q1 2018. 42 funds tracked by Wall St. Rank hold XENE as of Q2 2018.

  • Nexthera Capital reported no remaining Xenon Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Nexthera Capital sold 379,071 Xenon Pharmaceuticals shares in Q2 2018, an estimated $1.86M.
  • Nexthera Capital first reported a position in Xenon Pharmaceuticals in Q1 2018 and held it in 1 quarter.
  • Nexthera Capital's Xenon Pharmaceuticals position peaked at $1.86M in Q1 2018.
  • 42 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2018.

Based on Nexthera Capital's 13F filing for Q2 2018, filed 14 Aug 2018.